Allergan’s Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial

Allergan’s Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial

June 11, 2018 – Study meets primary endpoint for all doses and dose regimens – – Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over 12 weeks – – Allergan will continue with its

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

DUBLIN, May 29, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6×28 physicians sample pack, indicated

Allergan to Present at the Bank of America Merrill Lynch Healthcare Conference

DUBLIN, May 7, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nevada. The presentation will begin at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time)

Allergan: John Davidson Elected to Allergan Board of Directors

DUBLIN, May 3, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that John Davidson has been elected to its Board of Directors. Mr. Davidson and the other directors standing for re-election to Allergan’s Board were elected at Allergan’sAnnual General Meeting of Shareholders on May 2, 2018. With the addition

Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA) 2018 Annual Meeting

Eight accepted abstracts will showcase new data across schizophrenia, bipolar I disorder and major depressive disorder (MDD) DUBLIN, May 2, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that they will showcase new data during the upcoming American Psychiatric

Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action

— AboutYourGut.com Provides Resources and Education Focused on Irritable Bowel Syndrome with Diarrhea (IBS-D), Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) — DUBLIN and CAMBRIDGE, Mass., May 1, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals,

Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant — an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

– ACHIEVE II study demonstrates efficacy, safety and tolerability –– Study meets co-primary endpoints at 50 mg ubrogepant in second of two phase 3 studies –– Allergan plans US NDA filing in 2019 –— Allergan hosting a Conference call and

Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018

DUBLIN, April 26, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, will present new data at the annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Austin, Texas from April 27-30, 2018. Included is a post-hoc, exploratory, integrated analysis